After failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells ...
BMO Capital analyst Keith Tapper lowered the firm’s price target on Neurogene (NGNE) to $45 from $60 but keeps an Outperform rating on the ...
Keith Tapper CFA, an analyst from BMO Capital, maintained the Buy rating on Neurogene (NGNE – Research Report). The associated price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback